Rifampin NDC 24658-801

NDC codes

FDA NDC Directory

Product NDC (as listed)24658-801Labeler and product segments. Claims need a package NDC.

Product NDC at billing width24658-0801Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
24658-801-30	24658080130	30 CAPSULE in 1 BOTTLE (24658-801-30)Marketed from Mar 14, 2023

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Rifampin
Generic name (nonproprietary): rifampin
Active ingredients: Rifampin — 150 mg/1
Dosage form: Capsule
Route: Oral
Labeler: PURACAP LABORATORIES LLC DBA BLU PHARMACEUTICALS
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 064150
Marketing start: Mar 14, 2023
Listing expires: Dec 31, 2026
Other FDA classes: Rifamycins (Chemical structure)
Identifiers: Product ID 24658-801_1e50fbd4-91eb-4d25-a90d-1907c3a0ec02SPL ID 1e50fbd4-91eb-4d25-a90d-1907c3a0ec02SPL set ID 28109dee-3e5e-492b-b7d9-9ba46c0b5324RxCUI 198201, 198202UNII VJT6J7R4TRUPC 0324658801308, 0324658802602
Pharmacologic class: Rifamycin Antibacterial

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N424658080130 followed by a unit qualifier and the quantity

Package 24658-0801-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Mar 25, 2025.

Indications (excerpt from the label)

INDICATIONS AND USAGE In the treatment of both tuberculosis and the meningococcal carrier state, the small number of resistant cells present within large populations of susceptible cells can rapidly become the predominant type. Bacteriologic cultures should be obtained before the start of therapy to confirm the susceptibility of the organism to rifampin and they should be repeated throughout therapy to monitor the response to treatment. Since resistance can emerge rapidly, susceptibility tests should be performed in the event of persistent positive cultures during the course of treatment. If test results show resistance to rifampin and the patient is not responding to therapy, the drug regim…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 064150

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 064150
Product	Strength	Form · route	Labeler	Product NDC
Rifampin	Rifampin 300 mg/1	CapsuleOral	EPIC PHARMA, LLC	42806-799
Rifampin	Rifampin 150 mg/1	CapsuleOral	EPIC PHARMA, LLC	42806-801
Rifampin	Rifampin 150 mg/1	CapsuleOral	Coupler LLC	67046-1605
Rifampin	Rifampin 300 mg/1	CapsuleOral	PURACAP LABORATORIES LLC DBA BLU PHARMACEUTICALS	24658-802